EN | RU
EN | RU

Help Support

Back

Dotinurad: A valuable agent to treat hyperuricemic states in hypertensive people

Dotinurad: A valuable agent to treat hyperuricemic states in hypertensive people Dotinurad: A valuable agent to treat hyperuricemic states in hypertensive people
Dotinurad: A valuable agent to treat hyperuricemic states in hypertensive people Dotinurad: A valuable agent to treat hyperuricemic states in hypertensive people

What's new?

Both 2 mg and 4 mg dotinurad significantly drop serum uric acid in hypertensive patients with gout or hyperuricemia.

In a pooled analysis carried out by Toshinari Takahashi et al., dotinurad (a novel selective urate reabsorption inhibitor) was found to reduce serum uric acid levels in hypertensive individuals suffering from asymptomatic hyperuricemia or gout. The percentage of people who attained a serum uric acid level of ≤6.0 mg/dL was greater than 80% in both 2- and 4-mg groups. 

This study was conducted to investigate dotinurad's efficacy (uric acid-lowering effect) in 222 participants in four clinical trials. Furthermore, the investigators examined dotinurad's long-term uric acid-lowering effect  in 154 participants. Table 1 denotes the percent alteration in the levels of serum uric acid and the percentage of people attaining a serum uric acid level of ≤6.0 with dotinurad usage at a dose of 2 mg and 4 mg.


Dotinurad's long-term uric acid-lowering effect displayed almost comparable results. As found, concomitant usage of angiotensin II receptor blockers or diuretics influenced dotinurad's efficacy at only 2 mg dose. Dotinurad showed an achievement rate of more than 80% for serum uric acid level of ≤6.0 mg/dL in both the analyses and appears to be clinically valuable to manage hyperuricemic states in people with hypertension. 


Source:

Clinical and Experimental Hypertension

Article:

Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials

Authors:

Toshinari Takahashi et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: